摘要
目的:系统评价沙库巴曲缬沙坦对心力衰竭合并慢性肾脏病患者疗效的潜在价值.方法:系统检索PubMed、Embase、Cochrane、Clinicaltrials.gov、知网、维普和万方数据库,严格按照纳入及排除标准筛选文献,并对纳入的文献进行质量评价.对纳入的文献实验数据运用Revman 5.3软件进行meta分析.结果:纳入11篇RCT研究共8923名患者.荟萃分析结果显示,沙库巴曲缬沙坦较ACEI/ARB明显改善左心室射血分数及肾小球滤过率.沙库巴曲缬沙坦组左心室舒张末期内径、左心室收缩末期内径、收缩压和舒张压较对照组明显改善.两组间尿白蛋白/肌酐比值的改变无明显差异.结论:与ACEI或ARB相比,沙库巴曲缬沙坦显著提高左心室射血分数和肾小球滤过率,降低了血压、左心室舒张末期内径和左心室收缩末期内径,表明沙库巴曲缬沙坦能明显改善心力衰竭合并慢性肾脏病患者的心功能和肾功能.
Objective To systematically evaluate the potential value of sacubitril/valsartan in the treatment of heart failure complicated with chronic kidney disease.Methods PubMed,Embase,Cochrane,ClinicalTnials.gov,CNKI,VIP and Wanfang databases were systematially searched,literatures were screened strictly according to inclusion and exclusion criteria,and the quality of the included literatures was evaluated.Meta--analysis was performed on the experimental data of the included litera--ture using Revman 5.3 software.Results a total of 8923 patients were included in 11 RCTS.Results of meta-analysis showed that sacubitilvasartan signifcantly improved left ventricular ejection fraction and glomerular filtration rate.Left ventricular end-diastolic diameter,left ventricular end-systolie diameter,systolic blood pressure and diastolie blood pressure improved significantly compare with the control group.There was no significant difference in urinary albumin/creatinine ratio between the two groups.Conclusion Compared with ACEI or ARB,sacubitril/valsartan signifcantly inereased left ventricular ejection fraction and glomerular fltration rate,and decreased blood pressure,left ventricular end--diastolie diameter and left ventricular end-systolic diameter,suggesting that sacubirilvalsartan can significanly improve cardiac function and renal function in pa-tients with heart failure complicated with chronie kidney disease.
作者
李石松
蒋新华
Li Shi-song;Jiang Xin-hua(Affiliated Xiangdong Hospital of Hunan Normal University,Uling 412200,China)
出处
《晓庄学院学报（医学版）》
2022年第2期121-125,共5页
Journal of Hunan Normal University(Medical Sciences)
